Literature DB >> 2387095

A primed state exists in vivo following histological regression of amyloidosis.

P N Hawkins1, M B Pepys.   

Abstract

Using a sensitive, quantitative, and non-invasive in vivo method, based on the specific binding of serum amyloid P component to amyloid fibrils, we have directly documented the spontaneous resolution of AA amyloid deposits in mice, and the prolonged existence thereafter of a primed state of enhanced susceptibility to further amyloid deposition. These results may have important implications for understanding and management of amyloidosis in humans.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2387095      PMCID： PMC1535055          DOI： 10.1111/j.1365-2249.1990.tb03339.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  11 in total

1.  EXPERIMENTAL AMYLOIDOSIS: STUDIES WITH A MODIFIED CASEIN METHOD, CASEIN HYDROLYSATE AND GELATIN.

Authors:  D T JANIGAN
Journal:  Am J Pathol       Date:  1965-07       Impact factor: 4.307

2.  High efficiency iodination of monoclonal antibodies for radiotherapy.

Authors:  S J Mather; B G Ward
Journal:  J Nucl Med       Date:  1987-06       Impact factor: 10.057

Review 3.  Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

4.  Further characterization of amyloid-enhancing factor.

Authors:  M A Axelrad; R Kisilevsky; J Willmer; S J Chen; M Skinner
Journal:  Lab Invest       Date:  1982-08       Impact factor: 5.662

5.  Binding of serum amyloid P-component (SAP) by amyloid fibrils.

Authors:  M B Pepys; R F Dyck; F C de Beer; M Skinner; A S Cohen
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

6.  Imaging of experimental amyloidosis with 131I-labeled serum amyloid P component.

Authors:  D Caspi; S Zalzman; M Baratz; Z Teitelbaum; M Yaron; M Pras; M L Baltz; M B Pepys
Journal:  Arthritis Rheum       Date:  1987-11

7.  Isolation of human C-reactive protein and serum amyloid P component.

Authors:  F C De Beer; M B Pepys
Journal:  J Immunol Methods       Date:  1982       Impact factor: 2.303

8.  Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.

Authors:  M L Baltz; D Caspi; D J Evans; I F Rowe; C R Hind; M B Pepys
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

9.  Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component.

Authors:  P N Hawkins; M J Myers; J P Lavender; M B Pepys
Journal:  Lancet       Date:  1988-06-25       Impact factor: 79.321

10.  Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component.

Authors:  P N Hawkins; M J Myers; A A Epenetos; D Caspi; M B Pepys
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307
View more
  10 in total

1.  Where has secondary amyloid gone?

Authors:  B P Hazenberg; M H van Rijswijk
Journal:  Ann Rheum Dis       Date:  2000-08       Impact factor: 19.103

2.  Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice.

Authors:  Winston L Hutchinson; Jeff Herbert; Marina Botto; Mark B Pepys
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

3.  Longitudinal study of experimental induction of AA amyloidosis in mice seeded with homologous and heterologous AA fibrils.

Authors:  Naeem Muhammad; Tomoaki Murakami; Yasuo Inoshima; Naotaka Ishiguro
Journal:  Inflamm Res       Date:  2016-05-10       Impact factor: 4.575

4.  Long-term kinetics of AA amyloidosis and effects of inflammatory restimulation after disappearance of amyloid depositions in mice.

Authors:  N Muhammad; T Murakami; Y Inoshima; N Ishiguro
Journal:  Clin Exp Immunol       Date:  2015-04-23       Impact factor: 4.330

5.  Transmissibility of systemic amyloidosis by a prion-like mechanism.

Authors:  Katarzyna Lundmark; Gunilla T Westermark; Sofia Nyström; Charles L Murphy; Alan Solomon; Per Westermark
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

6.  Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Authors:  Karl Bodin; Stephan Ellmerich; Melvyn C Kahan; Glenys A Tennent; Andrzej Loesch; Janet A Gilbertson; Winston L Hutchinson; Palma P Mangione; J Ruth Gallimore; David J Millar; Shane Minogue; Amar P Dhillon; Graham W Taylor; Arthur R Bradwell; Aviva Petrie; Julian D Gillmore; Vittorio Bellotti; Marina Botto; Philip N Hawkins; Mark B Pepys
Journal:  Nature       Date:  2010-10-20       Impact factor: 49.962

Review 7.  Pathophysiology and treatment of systemic amyloidosis.

Authors:  Julian D Gillmore; Philip N Hawkins
Journal:  Nat Rev Nephrol       Date:  2013-08-27       Impact factor: 28.314

8.  Pathogenetic mechanisms of amyloid A amyloidosis.

Authors:  J Paul Simons; Raya Al-Shawi; Stephan Ellmerich; Ivana Speck; Samrina Aslam; Winston L Hutchinson; Palma P Mangione; Petra Disterer; Janet A Gilbertson; Toby Hunt; David J Millar; Shane Minogue; Karl Bodin; Mark B Pepys; Philip N Hawkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

9.  Accelerated resolution of AA amyloid in heparanase knockout mice is associated with matrix metalloproteases.

Authors:  Bo Wang; Ying-Xia Tan; Juan Jia; Andreas Digre; Xiao Zhang; Israel Vlodavsky; Jin-Ping Li
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

10.  Post mortem findings and their relation to AA amyloidosis in free-ranging Herring gulls (Larus argentatus).

Authors:  Désirée S Jansson; Caroline Bröjer; Aleksija Neimanis; Torsten Mörner; Charles L Murphy; Faruk Otman; Per Westermark
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.